Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America
Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Edmund K. Waller(Emory University), Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Kazunobu Kato(Otsuka (United States)), Ira Braunschweig(The University of Texas MD Anderson Cancer Center), Vijay Reddy(University of Florida), Damiano Rondelli(University of Illinois Chicago), James R. Mason(Sheba Medical Center), César O. Freytes(CHRISTUS Transplant Institute), Elizabeth Armstrong(Otsuka (United States)), Agnes Elekes(Otsuka (United States)), Weiyun Z. Ai(City College of San Francisco), Shin Mineishi(University of Alabama at Birmingham), Tsiporah B. Shore(Cornell University), Michael Craig(Edith Cowan University), Cathy Zhao(Otsuka (United States)), Angela Smith(Otsuka (United States)), Thomas C. Shea(University of North Carolina at Chapel Hill), Joseph W. Fay(Sheba Medical Center), Michael Lill(Cedars-Sinai Medical Center), William P. Vaughan(University of Pennsylvania Health System), Luciano J. Costa(University of Alabama at Birmingham)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k